KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Operating Income: 2017-2024

Historic Operating Income for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to -$30.8 million.

  • Aquestive Therapeutics' Operating Income fell 38.47% to -$11.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$55.8 million, marking a year-over-year decrease of 164.37%. This contributed to the annual value of -$30.8 million for FY2024, which is 103.75% down from last year.
  • As of FY2024, Aquestive Therapeutics' Operating Income stood at -$30.8 million, which was down 103.75% from -$15.1 million recorded in FY2023.
  • Aquestive Therapeutics' 5-year Operating Income high stood at -$15.1 million for FY2023, and its period low was -$42.9 million during FY2020.
  • Its 3-year average for Operating Income is -$29.3 million, with a median of -$30.8 million in 2024.
  • As far as peak fluctuations go, Aquestive Therapeutics' Operating Income surged by 64.10% in 2023, and later slumped by 103.75% in 2024.
  • Yearly analysis of 5 years shows Aquestive Therapeutics' Operating Income stood at -$42.9 million in 2020, then climbed by 19.15% to -$34.7 million in 2021, then declined by 21.30% to -$42.1 million in 2022, then surged by 64.10% to -$15.1 million in 2023, then tumbled by 103.75% to -$30.8 million in 2024.